This review paper, published in Frontiers in Oncology, provides a comprehensive update on the role of mitochondrial heat shock protein 90 (mtHsp90) in cancer. It synthesizes current knowledge on the structure, function, and therapeutic targeting of this molecular chaperone, which has emerged as a critical regulator of tumor metabolism and survival.
TL;DR
Mitochondrial Hsp90 (specifically TRAP1) acts as a "master switch" for metabolic reprogramming and apoptosis evasion in cancer cells while remaining nearly absent in healthy mitochondria. This review highlights the therapeutic potential of mtHsp90 inhibitors like gamitrinib, which are currently transitioning from successful preclinical models to human clinical trials.
What Problem Does This Paper Address?
Cancer cells thrive under high proteotoxic stress and have unique bioenergetic requirements (the "Warburg effect"). While cytoplasmic Hsp90 has been a drug target for decades, its mitochondrial counterpart, mtHsp90, represents a more selective "Achilles' heel."
The primary challenge addressed is the need for a unified understanding of how mtHsp90—comprising both TRAP1 and translocated cytoplasmic Hsp90—modulates tumor progression. Because mtHsp90 is highly expressed in tumor mitochondria but largely absent in normal ones, it offers a wider therapeutic window with potentially fewer off-target effects than traditional Hsp90 inhibitors.
Methods
As a systematic review, the authors analyze structural biology data, biochemical assays, and a vast array of preclinical/clinical studies. Key methodological focuses include:
- Structural Comparison: Analyzing the three-domain structure (NTD, MD, CTD) of TRAP1 vs. cytoplasmic Hsp90 isoforms.
- Functional Classification: Distinguishing between "foldase" activity (ATP-dependent protein remodeling) and "holdase" activity (ATP-independent stabilization of clients).
- Inhibitor Survey: Evaluating the chemical evolution of inhibitors, from early geldanamycin derivatives to mitochondria-targeted small molecules like gamitrinib-TPP.
Datasets
As this is a review article, it does not introduce a new primary dataset. Instead, it synthesizes results from:
- Preclinical Models: Dozens of in vitro cell lines (e.g., PC3 for prostate, H460 for lung, MDA-MB-231 for breast) and in vivo xenograft mouse models.
- Clinical Trial Registries: Data from ongoing trials such as NCT04827810 (Gamitrinib TPP) and NCT05257590 (CVM-1118).
- Structural Databases: Protein Data Bank (PDB) structures like 7KCM, which provided the first cryo-EM look at the TRAP1-SDHB complex.
Key Insights and Ideas
- Metabolic Gatekeeping: TRAP1 binds to and inhibits Succinate Dehydrogenase (SDH) and respiratory chain complex II. This inhibition suppresses oxidative phosphorylation (OXPHOS) and forces the cell toward aerobic glycolysis, a hallmark of tumor adaptation.
- Apoptosis Shield: mtHsp90 prevents the opening of the mitochondrial permeability transition pore (mPTP) by modulating cyclophilin D (CypD). This effectively raises the "death threshold" of the cancer cell, making it resistant to chemotherapy.
- The "Holdase" Autonomy: Unlike cytoplasmic Hsp90, TRAP1 can function as a "holdase" independently of ATP. This suggests that simply blocking the ATP-binding site might not completely halt its pro-tumorigenic functions.
- Mitochondrial Targeting: The most successful inhibitors (like gamitrinib) utilize a "mitochondriotropic" moiety (e.g., triphenylphosphonium or TPP) to achieve 1,000-fold higher concentration inside the mitochondria compared to the cytoplasm.
Key Results
- Gamitrinib Efficacy: Preclinical data across prostate, lung, and breast cancers show that gamitrinib induces rapid mitochondrial dysfunction and "mitochondrial apoptosis" without significant systemic toxicity.
- Synergy with Standard Care: In glioblastoma models, mtHsp90 inhibition sensitizes cells to temozolomide (TMZ), overcoming a major hurdle in brain cancer treatment.
- Clinical Progress: Two major drugs are in the pipeline:
- Gamitrinib TPP: Currently in Phase I for advanced cancers.
- CVM-1118 (Foslinanib): Currently in Phase II for various solid tumors, showing the ability to inhibit "vasculogenic mimicry" (the formation of blood-vessel-like structures by tumor cells).
Limitations and Future Work
- Import Mechanism: The exact mechanism by which cytoplasmic Hsp90 is translocated into the mitochondria remains a "black box" that requires further investigation.
- ATPase-Independent Roles: Since TRAP1 has significant "holdase" activity, future drug development may need to move beyond ATP-competitive inhibitors toward allosteric inhibitors that disrupt protein-protein interactions.
- Patient Stratification: There is a lack of clear biomarkers to predict which patients will respond best to mtHsp90-targeted therapies.
- Clinical Translation: While preclinical results are robust, the "valley of death" between mouse models and human efficacy remains a challenge, particularly regarding long-term safety and optimal dosing schedules.
Summary updated